Total Payments
$1.5M
2024 Payments
$239,187
Companies
23
Transactions
1,751
Medicare Patients
517
Medicare Billing
$40,677
Payment Breakdown by Category
Other$1.1M (70.8%)
Consulting$287,391 (19.2%)
Travel$111,269 (7.4%)
Food & Beverage$24,277 (1.6%)
Education$9,335 (0.6%)
Research$4,289 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 405 | 70.2% |
| Consulting Fee | $287,391 | 100 | 19.2% |
| Travel and Lodging | $111,269 | 411 | 7.4% |
| Food and Beverage | $24,277 | 797 | 1.6% |
| Education | $9,335 | 18 | 0.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,200 | 3 | 0.6% |
| Unspecified | $4,289 | 17 | 0.3% |
Payments by Type
General
$1.5M
1,734 transactions
Research
$4,289
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $378,762 | 512 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $279,018 | 289 | $0 (2024) |
| GENZYME CORPORATION | $216,268 | 161 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $172,519 | 190 | $0 (2024) |
| LEO Pharma Inc. | $109,132 | 96 | $0 (2024) |
| ABBVIE INC. | $88,881 | 111 | $0 (2024) |
| UCB, Inc. | $57,419 | 48 | $0 (2024) |
| Incyte Corporation | $39,693 | 40 | $0 (2024) |
| Janssen Biotech, Inc. | $39,029 | 129 | $0 (2024) |
| Dermavant Sciences, Inc. | $34,173 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $239,187 | 313 | UCB, Inc. ($48,508) |
| 2023 | $265,024 | 279 | Lilly USA, LLC ($71,127) |
| 2022 | $172,961 | 183 | Lilly USA, LLC ($46,584) |
| 2021 | $126,144 | 135 | GENZYME CORPORATION ($42,398) |
| 2020 | $153,795 | 111 | Novartis Pharmaceuticals Corporation ($51,734) |
| 2019 | $279,256 | 372 | Novartis Pharmaceuticals Corporation ($96,467) |
| 2018 | $190,845 | 267 | Lilly USA, LLC ($79,310) |
| 2017 | $66,641 | 91 | Novartis Pharmaceuticals Corporation ($39,306) |
All Payment Transactions
1,751 individual payment records from CMS Open Payments — Page 1 of 71
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $0.34 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Immunology | ||||||
| 12/13/2024 | LEO Pharma Inc. | — | Consulting Fee | Cash or cash equivalent | $5,882.50 | General |
| 12/13/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $27.52 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,240.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,240.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $31.08 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Immunology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: Immunology | ||||||
| 11/24/2024 | LEO Pharma Inc. | — | Travel and Lodging | Cash or cash equivalent | $660.84 | General |
| 11/24/2024 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $360.36 | General |
| 11/23/2024 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $137.44 | General |
| 11/22/2024 | LEO Pharma Inc. | — | Food and Beverage | Cash or cash equivalent | $54.19 | General |
| 11/19/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $330.50 | General |
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $85.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,786 | 3 |
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $1,770 | 7 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | ABBVIE INC. | $605.19 | 5 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 142 | 283 | $45,314 | $12,345 |
| 2022 | 5 | 125 | 252 | $36,934 | $10,369 |
| 2021 | 8 | 209 | 295 | $47,929 | $14,573 |
| 2020 | 2 | 41 | 58 | $10,609 | $3,389 |
Total Patients
517
Total Services
888
Medicare Billing
$40,677
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 97 | $21,825 | $5,823 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 24 | $7,525 | $2,310 | 30.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 18 | 22 | $6,150 | $2,083 | 33.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 26 | 41 | $7,339 | $1,623 | 22.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 17 | 99 | $2,475 | $505.85 | 20.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 77 | $17,325 | $5,132 | 29.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 18 | $5,400 | $1,786 | 33.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 16 | 19 | $5,215 | $1,584 | 30.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 25 | 36 | $6,444 | $1,347 | 20.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 20 | 102 | $2,550 | $519.95 | 20.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 64 | 77 | $15,485 | $5,085 | 32.8% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 23 | 29 | $7,685 | $2,487 | 32.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 19 | $5,232 | $1,842 | 35.2% |
| 17000 | Destruction of skin growth | Office | 2021 | 33 | 39 | $6,981 | $1,496 | 21.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 18 | 18 | $4,552 | $1,248 | 27.4% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 14 | 16 | $3,520 | $1,202 | 34.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 20 | 22 | $2,599 | $799.90 | 30.8% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 22 | 75 | $1,875 | $413.80 | 22.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 14 | 23 | $5,244 | $1,713 | 32.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 27 | 35 | $5,364 | $1,677 | 31.3% |
About Benjamin Ehst, M.D., PH.D
Benjamin Ehst, M.D., PH.D is a Dermatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740320068.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Benjamin Ehst, M.D., PH.D has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $239,187 received in 2024. These payments were reported across 1,751 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Ehst has provided services to 517 Medicare beneficiaries, totaling 888 services with total Medicare billing of $40,677. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Portland, OR
- Active Since 02/07/2007
- Last Updated 06/03/2019
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1740320068
Products in Payments
- COSENTYX (Biological) $240,963
- DUPIXENT (Biological) $223,033
- TALTZ (Drug) $222,743
- OLUMIANT (Drug) $87,136
- DUPIXENT (Drug) $65,739
- ADBRY (Biological) $62,518
- DUPIXENT DUPILUMAB INJECTION (Biological) $54,216
- Bimzelx (Biological) $48,508
- RINVOQ (Biological) $46,810
- SKYRIZI (Biological) $39,560
- OPZELURA (Drug) $36,543
- VTAMA (Drug) $34,173
- TREMFYA (Drug) $27,018
- Olumiant (Drug) $25,190
- Sotyktu (Drug) $21,736
- Tremfya (Drug) $11,774
- SILIQ (Drug) $10,581
- COSENTYX (Drug) $8,394
- ILUMYA (Biological) $8,263
- DUOBRII (Drug) $5,718
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Portland
Andrew Blauvelt, Md, MD
Dermatology — Payments: $2.6M
Dermatology $2.6M
Eric Simpson, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Jason Hawkes, Md, Ms, MD, MS
Dermatology — Payments: $876,779
Dermatology $876,779
Dr. Omar Qutub, Md, MD
Dermatology — Payments: $73,858
Dermatology $73,858
Alex Ortega Loayza, Md, MD
Dermatology — Payments: $72,824
Dermatology $72,824
Jon Hanifin, Md, MD
Dermatology — Payments: $66,868
Dermatology $66,868